Proleukin is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Clinigen Group Plc. The primary component is Aldesleukin.
| Product ID | 76310-022_3b04162e-e9f0-4fea-9dc0-62a9ebd6ef9e |
| NDC | 76310-022 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Proleukin |
| Generic Name | Aldesleukin |
| Dosage Form | Injection, Powder, Lyophilized, For Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 1992-05-05 |
| Marketing Category | BLA / BLA |
| Application Number | BLA103293 |
| Labeler Name | Clinigen Group PLC |
| Substance Name | ALDESLEUKIN |
| Active Ingredient Strength | 1 mg/mL |
| Pharm Classes | Increased Lymphocyte Activation [PE],Increased Lymphocyte Cell Production [PE],Interleukin-2 [CS],Lymphocyte Growth Factor [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
| Marketing Start Date | 2019-12-31 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | BLA |
| Application Number | BLA103293 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2019-12-31 |
| Ingredient | Strength |
|---|---|
| ALDESLEUKIN | 1.1 mg/mL |
| SPL SET ID: | deead498-9f19-48cf-87c7-6caf2263f2ab |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 65483-116 | Proleukin | aldesleukin |
| 76310-022 | Proleukin | aldesleukin |
| 17089-380 | GUNA-IL 2 | ALDESLEUKIN |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() PROLEUKIN 86330987 4761828 Live/Registered |
CLINIGEN HOLDINGS LIMITED 2014-07-08 |
![]() PROLEUKIN 85199293 not registered Dead/Abandoned |
Novartis Vaccines & Diagnostics, Inc. 2010-12-16 |
![]() PROLEUKIN 79062942 3639936 Dead/Cancelled |
Novartis AG 2008-08-07 |
![]() PROLEUKIN 76532544 2857698 Dead/Cancelled |
Chiron Corporation 2003-07-25 |
![]() PROLEUKIN 73523710 1369770 Live/Registered |
CETUS CORPORATION 1985-02-25 |